Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
NEW YORK, Feb. 06, 2017 -- Safirstein Metcalf LLP announces that a class action complaint was filed against DaVita Inc. (“DaVita”) (NYSE:DVA) in the U.S. District Court for the District of Colorado. The complaint is brought on behalf of all purchasers of DaVita securities between August 5, 2015 and October 21, 2016 (the “Class Period”) for alleged violations of the Securities Exchange Act of 1934.
If you purchased DaVita securities during the class period, and would like more information about getting involved in the DaVita Shareholder Class Action, please contact Sheila Feerick at 1-800-221-0015, or email [email protected].
If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
DaVita, Inc. Shareholder Class Action
TICKER: DVA
Common Stock CUSIP: 23918K108
Class Period: August 5. 2015 – October 21, 2016
Lead Plaintiff Date: April 3, 2017
According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using the American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
